Wall Street Zen Downgrades MiNK Therapeutics (NASDAQ:INKT) to Sell

MiNK Therapeutics (NASDAQ:INKT) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

INKT has been the subject of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $35.00.

MiNK Therapeutics Stock Up 0.5%

Shares of NASDAQ:INKT opened at $11.59 on Friday. The firm has a fifty day simple moving average of $12.75 and a two-hundred day simple moving average of $13.54. MiNK Therapeutics has a 52 week low of $4.56 and a 52 week high of $76.00. The stock has a market capitalization of $54.36 million, a P/E ratio of -3.83 and a beta of 0.35.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.21. On average, analysts expect that MiNK Therapeutics will post -2.75 earnings per share for the current year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.